4th Quarter - Report

FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC

Firm
Client
Income
—
Expenses
$430,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Drug Shortages and Medicaid Specialty Drug Pharmacy Payment Reform

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —

Contacted: HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); SENATE

Health Issues HCR

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act US Drug Enforcement Administration Quota FDA/PTO Coordination USPTO Practices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Domestic Manufacturing Tariffs Medical Devices Generic Medicines Industry Net Effective Cost Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

LobbyistCovered position, as disclosed
CRAIG BURTON —
SARAH CHRISTINE D'ORSIE —
STU EVENHAUGEN New Dir. of Pol. Analysis & Evaluation, Off. of the Assist. Sec. of Defense for Health Affairs; Strategy & Pol. Analyst, US Dept. of Health & Human Serv.; Sen. Risk Analyst, US Dept. of Homeland Sec.; Pol. Analyst, U.S. Dept. of Health & Human Services
CHRISTOPHER LEIBUNDGUTH New N/A
STEVEN CHASE WALKER —

Contacted: Centers For Medicare and Medicaid Services (CMS); White House Office; Defense, Dept of (DOD); Food & Drug Administration (FDA); Office of Management & Budget (OMB); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Bills named: S. 1414 (119th), S. 1954 (119th), H.R. 5526 (119th), S. 2276 (119th), H.R. 3269 (119th)

Manufacturing MAN

Domestic Manufacturing

LobbyistCovered position, as disclosed
CRAIG BURTON —
STU EVENHAUGEN New Dir. of Pol. Analysis & Evaluation, Off. of the Assist. Sec. of Defense for Health Affairs; Strategy & Pol. Analyst, US Dept. of Health & Human Serv.; Sen. Risk Analyst, US Dept. of Homeland Sec.; Pol. Analyst, U.S. Dept. of Health & Human Services

Contacted: Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); White House Office; Commerce, Dept of (DOC)

Copyright/Patent/Trademark CPT

PTAB Discretionary Denials

LobbyistCovered position, as disclosed
SARAH CHRISTINE D'ORSIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office

Trade (domestic/foreign) TRD

Drug Shortages Domestic Manufacturing Tariffs Medical Devices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Generic Medicines

LobbyistCovered position, as disclosed
CRAIG BURTON —
SARAH CHRISTINE D'ORSIE —
STU EVENHAUGEN New Dir. of Pol. Analysis & Evaluation, Off. of the Assist. Sec. of Defense for Health Affairs; Strategy & Pol. Analyst, US Dept. of Health & Human Serv.; Sen. Risk Analyst, US Dept. of Homeland Sec.; Pol. Analyst, U.S. Dept. of Health & Human Services
CHRISTOPHER LEIBUNDGUTH New N/A

Contacted: U.S. Trade Representative (USTR); SENATE; White House Office; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.